Fabry Disease

Overview

Plain-Language Overview

Fabry Disease is a rare inherited disorder that affects the body's ability to break down certain fatty substances. It primarily impacts the nervous system, kidneys, heart, and skin. This condition results from a deficiency of an enzyme called alpha-galactosidase A, leading to the buildup of a fatty material called globotriaosylceramide in cells. Over time, this accumulation causes damage to blood vessels and organs, leading to symptoms like pain, skin rashes, kidney problems, and heart issues. The disease can affect both children and adults and often worsens with age.

Clinical Definition

Fabry Disease is an X-linked lysosomal storage disorder caused by mutations in the GLA gene, resulting in deficient activity of the enzyme alpha-galactosidase A. This deficiency leads to systemic accumulation of the glycosphingolipid globotriaosylceramide (Gb3) within lysosomes of vascular endothelial cells, smooth muscle cells, and various organ tissues. The progressive accumulation causes multisystemic involvement, including neuropathic pain, angiokeratomas, renal failure, cardiomyopathy, and cerebrovascular disease. It is clinically significant due to its chronic course and potential for severe organ damage if untreated. Males typically present with more severe symptoms, while heterozygous females may have variable manifestations due to X-chromosome inactivation.

Inciting Event

The disease is caused by an inherited mutation in the GLA gene leading to enzyme deficiency.
No external environmental triggers are required; disease onset is due to genetic enzyme deficiency.
Symptom onset may be precipitated by stress, fever, or exercise exacerbating ischemic pain.

Latency Period

Symptoms often begin in childhood or adolescence but diagnosis may be delayed for decades.
Progressive accumulation of Gb3 leads to gradual onset of neuropathic pain and organ dysfunction.
Clinical manifestations may not appear until early adulthood despite lifelong enzyme deficiency.

Diagnostic Delay

Early symptoms such as acroparesthesias and angiokeratomas are often misattributed to other causes.
Lack of awareness and rarity of the disease contribute to delayed diagnosis.
Variable symptom severity in females leads to under-recognition.
Overlap with common conditions like Fabry-unrelated neuropathies or cardiomyopathies causes misdiagnosis.

Clinical Presentation

Signs & Symptoms

Neuropathic pain (burning, tingling) in hands and feet starting in childhood or adolescence.
Angiokeratomas appearing as clusters of dark red skin lesions in the lower trunk.
Hypohidrosis or decreased sweating leading to heat intolerance.
Gastrointestinal symptoms including abdominal pain and diarrhea.
Progressive renal dysfunction manifesting as proteinuria and eventual renal failure.

History of Present Illness

Patients typically report episodic burning pain in the hands and feet (acroparesthesias) starting in childhood.
History of hypohidrosis or heat intolerance is common due to autonomic dysfunction.
Cutaneous findings include angiokeratomas primarily in the bathing trunk area.
Progressive symptoms include proteinuria, renal insufficiency, and cardiac symptoms such as palpitations or chest pain.
Some patients experience transient ischemic attacks or strokes in early adulthood.

Past Medical History

History of chronic neuropathic pain or unexplained renal disease is common.
Previous episodes of gastrointestinal symptoms like abdominal pain or diarrhea may be reported.
Prior cardiac evaluations may reveal left ventricular hypertrophy or arrhythmias without clear etiology.
No history of environmental toxin exposure is typically relevant.

Family History

Positive family history of Fabry disease or unexplained renal failure, stroke, or cardiomyopathy in male relatives.
X-linked inheritance pattern with affected males and carrier females.
Female relatives may have mild or variable symptoms due to X-chromosome inactivation.
Family members may have undergone enzyme activity testing or genetic analysis confirming GLA mutations.

Physical Exam Findings

Angiokeratomas: clusters of small, dark red to black papules typically found in the lower trunk and groin.
Corneal verticillata: whorl-like corneal opacities visible on slit-lamp examination without affecting vision.
Left ventricular hypertrophy detected by cardiac auscultation or imaging due to cardiac involvement.
Peripheral neuropathy signs such as decreased sensation or pain in a glove-and-stocking distribution.
Proteinuria or signs of renal impairment such as edema or hypertension.

Diagnostic Workup

Diagnostic Criteria

Diagnosis of Fabry Disease is established by demonstrating deficient alpha-galactosidase A enzyme activity in males, typically via leukocyte or plasma assay. In females, enzyme activity may be normal or mildly reduced, so genetic testing for pathogenic GLA mutations is essential for confirmation. Additional supportive findings include elevated plasma or urine levels of globotriaosylceramide (Gb3) or its deacylated form, lyso-Gb3. Clinical features such as characteristic angiokeratomas, corneal verticillata, and family history further support the diagnosis.

Pathophysiology

Key Mechanisms

Deficiency of the lysosomal enzyme alpha-galactosidase A due to mutations in the GLA gene leads to accumulation of globotriaosylceramide (Gb3) in vascular endothelial cells and multiple tissues.
Gb3 accumulation causes progressive vascular endothelial dysfunction, leading to ischemia and organ damage.
Involvement of small blood vessels results in neuropathic pain and angiokeratomas.
Deposition in the renal glomeruli causes proteinuria and progressive renal failure.
Cardiac accumulation leads to left ventricular hypertrophy and arrhythmias.

Involvement	Details
Organs	Kidneys are commonly affected, with progressive proteinuria and renal failure being major causes of morbidity.
	Heart involvement includes left ventricular hypertrophy, arrhythmias, and heart failure.
	Skin shows characteristic angiokeratomas due to vascular endothelial glycolipid accumulation.
Tissues	Vascular endothelium is critically involved due to glycolipid accumulation causing ischemic injury and angiokeratomas.
	Myocardial tissue undergoes hypertrophy and fibrosis resulting in cardiomyopathy.
	Renal glomerular and tubular tissues are damaged by glycolipid deposits leading to progressive renal failure.
Cells	Endothelial cells accumulate globotriaosylceramide causing vascular dysfunction and ischemia.
	Cardiomyocytes exhibit glycolipid storage leading to hypertrophy and fibrosis.
	Podocytes in the kidney accumulate glycolipids contributing to proteinuria and glomerulosclerosis.
Chemical Mediators	Alpha-galactosidase A deficiency leads to accumulation of globotriaosylceramide, the primary pathogenic substrate.
	Globotriaosylceramide (Gb3) accumulation triggers cellular dysfunction and inflammation.
	Lyso-Gb3 is a deacylated derivative of Gb3 that promotes fibrosis and vascular injury.

Treatments

Pharmacological Treatments

Enzyme replacement therapy (agalsidase beta or agalsidase alfa)
- Mechanism:
  - Replaces deficient alpha-galactosidase A enzyme to reduce globotriaosylceramide accumulation
- Side effects:
  - Infusion reactions
  - Antibody formation
  - Headache
- Clinical role:
  - First-line
Migalastat
- Mechanism:
  - Pharmacological chaperone that stabilizes certain mutant forms of alpha-galactosidase A to enhance its activity
- Side effects:
  - Headache
  - Nausea
  - Upper respiratory tract infection
- Clinical role:
  - First-line for amenable mutations
Pain management (e.g., gabapentin, carbamazepine)
- Mechanism:
  - Modulates neuropathic pain pathways to relieve acroparesthesias
- Side effects:
  - Dizziness
  - Sedation
  - Ataxia
- Clinical role:
  - Supportive
Angiotensin-converting enzyme inhibitors (ACE inhibitors) or angiotensin receptor blockers (ARBs)
- Mechanism:
  - Reduce proteinuria and slow progression of Fabry nephropathy by lowering intraglomerular pressure
- Side effects:
  - Hyperkalemia
  - Hypotension
  - Cough (ACE inhibitors)
- Clinical role:
  - Adjunctive

Non-pharmacological Treatments

Regular monitoring of renal function and cardiac status to detect and manage complications early.
Lifestyle modifications including low-sodium diet and blood pressure control to reduce renal and cardiovascular risk.
Pain management with physical therapy and avoidance of triggers for neuropathic pain episodes.
Renal replacement therapy such as dialysis or kidney transplantation in end-stage renal disease.

Prevention

Pharmacological Prevention

Enzyme replacement therapy (ERT) with recombinant alpha-galactosidase A to reduce substrate accumulation.
Chaperone therapy (e.g., migalastat) for amenable GLA mutations to stabilize residual enzyme activity.
ACE inhibitors or ARBs to reduce proteinuria and slow renal disease progression.
Antiplatelet agents to reduce stroke risk in patients with cerebrovascular involvement.
Pain management with anticonvulsants or antidepressants for neuropathic pain control.

Non-pharmacological Prevention

Regular screening for renal, cardiac, and cerebrovascular complications to enable early intervention.
Avoidance of extreme temperatures to prevent pain crises and hypohidrosis complications.
Genetic counseling for affected families to inform reproductive decisions.
Lifestyle modifications including blood pressure control and smoking cessation to reduce vascular risk.
Physical therapy to maintain mobility and manage neuropathic symptoms.

Outcome & Complications

Complications

End-stage renal disease requiring dialysis or transplantation.
Heart failure secondary to restrictive or hypertrophic cardiomyopathy.
Ischemic stroke from small vessel disease and vascular endothelial dysfunction.
Arrhythmias including atrial fibrillation and conduction blocks.
Chronic neuropathic pain severely impairing quality of life.

Short-term Sequelae	Long-term Sequelae
Acute pain crises triggered by temperature changes or stress. Transient ischemic attacks due to cerebrovascular involvement. Episodes of gastrointestinal discomfort such as cramping and diarrhea. Exacerbation of neuropathic symptoms during febrile illnesses. Hypertensive episodes secondary to renal impairment.	Progressive renal failure leading to dialysis dependence. Chronic heart failure from ongoing myocardial fibrosis and hypertrophy. Permanent neurological deficits including sensory loss and stroke sequelae. Hearing impairment progressing to deafness. Psychosocial disability due to chronic pain and organ dysfunction.

Differential Diagnoses

Fabry Disease versus Metachromatic Leukodystrophy

Fabry Disease	Metachromatic Leukodystrophy
X-linked recessive inheritance	Autosomal recessive inheritance
Deficiency of alpha-galactosidase A enzyme	Deficiency of arylsulfatase A enzyme
Multisystemic glycosphingolipid accumulation with predominant angiokeratomas and neuropathic pain	Progressive demyelination with central and peripheral nervous system involvement

Fabry Disease versus Pompe Disease

Fabry Disease	Pompe Disease
X-linked recessive inheritance	Autosomal recessive inheritance
Deficiency of alpha-galactosidase A enzyme	Deficiency of acid alpha-glucosidase (acid maltase)
Cardiac involvement with left ventricular hypertrophy but less severe than infantile Pompe	Severe cardiomegaly and hypertrophic cardiomyopathy in infancy

Fabry Disease versus Hereditary Angioedema

Fabry Disease	Hereditary Angioedema
X-linked recessive inheritance	Autosomal dominant inheritance
Normal complement levels, enzyme deficiency unrelated to complement	Low C1 esterase inhibitor levels or function
Chronic angiokeratomas and neuropathic pain	Recurrent episodes of nonpruritic angioedema without rash

Fabry Disease versus Multiple Sclerosis

Fabry Disease	Multiple Sclerosis
Childhood or adolescence onset possible but often earlier	Typically young adult onset (20-40 years)
Progressive neuropathic pain and systemic symptoms	Relapsing-remitting neurological deficits
No CNS plaques; instead, lysosomal storage seen on biopsy	Multiple demyelinating plaques in CNS white matter on MRI

Fabry Disease versus Diabetic Neuropathy

Fabry Disease	Diabetic Neuropathy
No diabetes history; genetic enzyme deficiency	History of chronic hyperglycemia and diabetes mellitus
Neuropathic pain with characteristic angiokeratomas	Symmetric distal sensory loss and pain without skin lesions
Normal glucose metabolism; low alpha-galactosidase A activity	Elevated blood glucose and HbA1c